Associazione Nazionale Medici Cardiologi Ospedalieri

congress.anmco.it

CONGRESS ABSTRACT

CONGRESS ABSTRACT

OPTIMIZATION OF MEDICAL THERAPY IN PATIENTS WITH HFMREF AND HFPEF: DATA FROM THE PONTE SC-SCA REGISTRY

Gianpaolo Palmieri Foggia (Foggia) – Policlinico Riuniti | Crudo Andrea Foggia (Foggia) – Policlinico Riuniti | Citarelli Gaetano Bari (Bari) – Ospedale San Paolo | Iacoviello Massimo Foggia (Foggia) – Policlinico Riuniti | Scicchitano Pietro Altamura (Bari) – Ospedale Perinei | De Gennaro Luisa Bari (Bari) – Ospedale San Paolo | Massari Francesco Altamura (Bari) – Ospedale Perinei | Bonfantino Massimo Vincenzo Bari (Bari) – Ospedale Di Venere | Brunetti Natale Daniele Foggia (Foggia) – Policlinico Riuniti | Campanella Cosimo Bari (Bari) – Ospedale San Paolo | Colonna Paolo Bari (Bari) – Policlinico Di Bari | Dalena Giangiuseppe Putignano (Bari) – Ospedale Santa Maria Degli Angeli | Passantino Andrea Bari (Bari) – Istituti Clinici Scientifici Maugeri IRCCS, Cardiac Rehabilitation Unit Of Bari Institute | Pisanò Ennio Brindisi (Brindisi) – Ospedale Perrino | Nardi Federico Casale Monferrato (Alessandria) – Ospedale Santo Spirito | Colivicchi Furio Roma (Roma) – Presidio Ospedaliero San Filippo Neri – Asl Roma 1 | Oliva Fabrizio Milanoo (Milanoo) – ASST Grande Ospedale Metropolitano Niguarda | Gabrielli Domenico Roma (Roma) – Azienda Ospedaliera San Camillo Forlanini | Grimaldi Massimo Acquaviva Delle Fonti (Bari) – Ospedale Miulli | Caldarola Pasquale Bari (Bari) – Ospedale San Paolo

Background & Study Aim. In recent years, significant progress has been made not only in the treatment of heart failure with reduced ejection fraction (HFrEF) but also in patients with mildly reduced (HFmrEF) and preserved ejection fraction (HFpEF). This study aimed to evaluate the management of HFmrEF and HFpEF patients within the PONTE SC/SCA registry. Methods and Results. Between January 2024 and September 2025, 1,203 patients were enrolled, including 189 with HFmrEF and 302 with HFpEF. Prescribed pharmacological therapy was analyzed, focusing on angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB), angiotensin receptor–neprilysin inhibitors (ARNI), beta-blockers, mineralocorticoid receptor antagonists (MRA), and sodium–glucose co-transporter 2 inhibitors (SGLT2i). As shown in the figure, ACEi/ARB/ARNI, beta-blockers, and MRA were prescribed in a high proportion of cases, whereas SGLT2i use was more limited, particularly among HFpEF patients. Conclusions. The PONTE SC/SCA registry demonstrates partial optimization of therapy in HFmrEF and HFpEF patients, especially regarding SGLT2i use. These findings provide valuable insights for further improving diagnostic and therapeutic pathways in heart failure and highlight the importance of a regional registry as a tool for monitoring and optimizing patient care.